Is endorectal coil necessary for the staging of clinically localized prostate cancer? Comparison of non-endorectal versus endorectal MR imaging.
OBJECTIVE
The goal of this study was to compare the diagnostic use and safety of endorectal coil (ERC) MRI with those of phased-array coil MRI.


METHODS
We retrospectively included 91 consecutive patients who had undergone 1.5-T MRI with ERC or with phased-array coil MRI before radical prostatectomy at our institution. We compared 47 patients' phased-array coil MRI and 44 patients' ERC-MRI with histologic findings. We also evaluated adverse events following the MRI procedure.


RESULTS
The serum PSA levels ranged from 2.85 to 33.51 ng/mL (10.72 ± 1.9), and the median Gleason score was 7 (range 4-9). The mean interval between diagnostic prostate biopsy and staging MRI was 18.4 days (range 2-37). In assessing organ-confined disease, extracapsular extension and seminal vesicle invasion by MRI, there were no significant differences between ERC-MR group and phased-array coil MR group. The AUC values were 0.671 (95% CI 0.530-0.813) for ERC-MR and 0.657 (95% CI 0.503-0.811) for phased-array coil MR. No significant differences were found between the two groups (p = 0.24). Five patients (11.4%) developed rectal complications after ERC-MRI. However, no complications were found in phased-array coil MRI group.


CONCLUSIONS
In terms of diagnostic accuracy and comfort of patients, the use of ERC-MRI did not significantly improve the staging of prostate cancer and presented several complications. Therefore, phased-array coil MRI is a better alternative considering comorbidity.
Lee
Seung Hwan
SH
Department of Urology, Yonsei University Health System, Gangnam Severance Hospital, P.O. Box 1217, Seoul, Korea.
Park
Kyung Kgi
KK
Choi
Kyung Hwa
KH
Lim
Beom Jin
BJ
Kim
Joo Hee
JH
Lee
Seung Wook
SW
Chung
Byung Ha
BH
D000328:Adult; D000368:Aged; D001706:Biopsy; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000009:adverse effects / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000009:adverse effects / Q000379:methods*; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology*; D012189:Retrospective Studies; D012680:Sensitivity and Specificity
D017430:Prostate-Specific Antigen